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Abstract Botulinum neurotoxins (BoNTs) cause the disease
botulism, which can be lethal if untreated. There are seven
known serotypes of BoNT, A–G, defined by their response to
antisera. Many serotypes are distinguished into differing sub-
types based on amino acid sequence, and many subtypes are
further differentiated into toxin variants. Previous work in our
laboratory described the use of a proteomics approach to
distinguish subtype BoNT/A1 from BoNT/A2 where BoNT
identities were confirmed after searching data against a data-
base containing protein sequences of all known BoNT/A
subtypes. We now describe here a similar approach to
differentiate subtypes BoNT/B1, /B2, /B3, /B4, and /B5.
Additionally, toidentifynewsubtypesorhithertounpublished
amino acid substitutions, we created an amino acid substitu-
tion database covering every possible amino acid change. We
used this database to differentiate multiple toxin variants
within subtypes of BoNT/B1 and B2. More importantly, with
our amino acid substitution database, we were able to identify
anovelBoNT/Bsubtype,designatedhereasBoNT/B7.These
techniques allow for subtype and strain level identification of
both known and unknown BoNT/B rapidly with no DNA
required.
Keywords Botulinumneurotoxin.Botulism.Mass
spectrometry.Proteomics
Introduction
Botulism is a potentially fatal disease caused by exposure to
botulinum neurotoxins (BoNTs), 150 kDa protein neurotox-
ins. In vivo, BoNTs halt nerve impulses by cleaving proteins
necessary for acetylcholine release into the neuromuscular
junction. This leads to a flaccid paralysis, which can affect
respiration and may necessitate ventilator support for the
patient [1]. BoNT is the most lethal toxin known with an
estimated oral LD50 of approximately 70 μg for the average
human [1]. This extreme toxicity has led, in part, to the
BoNT’s current CDC designation as a category A select
agent for bioterrorism, making it one of the most likely
agents for bioterrorism [1]. Botulism patients receive a
serotype-specific immunoglobulin products that are most
effective when administered within 24 h of exposure [2].
Therefore rapid determination of exposure and identification
of the BoNT serotype is an important public health goal.
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which are defined by their ability to be neutralized by an
antiserum that was produced using a specific BoNT. Nucle-
otide or amino acid sequence variation within BoNTs in
strains of a serotype has led to the designation of subtypes.
Historically, subtypes have been defined by distinct cultural/
biochemical characteristics [3], functional differences [4], or
differential binding of monoclonal antibodies (mAbs) [5–7].
Within the BoNT/B serotype, there are currently six known
subtypes, B1–B6 [8–11]. The B1–B6 subtypes exhibit ami-
no acid variation of 7% or less. In addition, there is amino
acid variation within a subtype, such as 1.5% within B2 or
1.7% within B4 subtypes. This variation could be a new
strain (Clostridium organism) or toxin variant (neurotoxin
protein), with some the neurotoxin of some strains having as
few as a single amino acid difference, or 0.08% difference.
Identification of the subtype of BoNT is important for
several reasons. First, one definition of a subtype of BoNT
indicates that different subtypes of toxin might have differ-
ential binding to monoclonal antibodies, and perhaps some
polyclonal antibodies as well [4,11]. This becomes impor-
tant as researchers search for an alternative treatment to the
currently used equine immunoglobulin approach to treat
botulism. Various mAb could be proposed as immunoglob-
ulin treatments for botulism; however, if there is differential
binding of these antibodies to different subtypes, care must
be taken in choosing which antibodies to use as treatment, as
the antibodies might not be effective at neutralizing all
subtypes of BoNT within a serotype. Secondly, identifica-
tion of the BoNT subtype could be important to epidemiol-
ogy and forensic investigations attempting to trace the origin
of the toxin and its spread in a botulism incident. Concurrent
outbreaks of botulism could be identified as originating
from the identical or diverse sources based upon the subtype
of toxin present.
We previously described methods to identify the serotype
A subtypes BoNT/A1 or /A2 and the serotype B subtypes
BoNT/B1 or /B4 using mass spectrometry [12,13]. Our
methods involve a tryptic digestion of the toxin and
matrix-assisted laser desorption/ionization time of flight
(MALDI-TOF) or liquid chromatography–tandem mass
spectrometry (LC-MS/MS) analysis of the tryptic fragments,
followed by querying the data to a protein database that
contains entries from the different BoNT subtypes. The
subtypes BoNT/A1 and /A2 are approximately 10% differ-
ent from each other, and the LC-MS/MS analysis was able
to detect over half (58%) of the theoretical differences
between BoNT/A1 and /A2 or 76 of the 131 residues [12].
MS/MS identification of the 76 amino acid differences
provided a clear distinction of BoNT/A1 from /A2.
Currently, subtype identification is determined through
DNA sequencing of the toxin’s genes [10]. Other DNA
analysis techniques such as pulsed field gel electrophoresis
[14], randomly amplified polymorphic DNA analysis [15],
amplified fragment-length polymorphism analysis [16],
flaA variable-region sequencing [17], multilocus sequence
typing [18], multiple locus variable-number tandem repeat
analysis [19], and a comparative genomic hybridization
microarray [20] have also been used to differentiate strains.
All of these methods rely on the presence of bacterial DNA
in the sample material. However, BoNT can be present in a
clarified or filtered sample in which the bacterium is absent.
In such a situation, toxin subtype identification or strain
characterization would be difficult, but perhaps possible,
using traditional DNA-based methods [19,21] as clarified
samples can contain small amounts of DNA depending on
the degree of purity. If DNA is not present, then these DNA-
based methods cannot be used for subtype identification.
Our method to distinguish the two BoNT/A subtypes
from each other relied upon searching a database of existing
proteins, which does not allow de novo identification of a
new subtype or toxin variant of BoNT. De novo identifica-
tion of a new subtype or variant within a BoNT subtype is
just as important, if not more so, than classification of a
sample as an existing subtype. In this work, we demonstrate
our ability to first distinguish BoNT/B1, /B2, /B3, /B4, and /
B5 subtypes from each other using mass spectrometry and
the ability to distinguish multiple toxin variants within
BoNT/B1 and /B2 subtypes using a amino acid substitution
database that includes all possible amino acid substitutions
of BoNT/B1. Finally, we describe the use of the amino acid
substitution database approach to identify a novel subtype of
BoNT/B, designated here as BoNT/B7. The study combines
the use of mass spectrometry with the amino acid substitu-
tion database to provide a powerful tool that can be used to
screen samples for new BoNT/B toxin variants or subtypes
with no DNA needed.
Experimental procedures
Materials
BoNT is highly toxic and requires appropriate safety meas-
ures. All neurotoxins were handled in a class 2 biosafety
cabinet equipped with HEPA filters. Commercially purified
BoNT/B1 complex toxin was purchased (Metabiologics,
Madison, WI, USA). Dynabeads® Protein G were pur-
chased (Invitrogen, Carlsbad, CA, USA) at 1.3 g/cm
3 in
phosphate-buffered saline (PBS), pH 7.4, containing 0.1%
Tween® 20 and 0.02% sodium azide. Sequencing-grade
modified trypsin at 0.5 mg/mL in 50-mM acetic acid and
sequencing grade chymotrypsin at 1 μg/μL in 50-mM am-
monium bicarbonate was purchased (Roche, Pleasanton,
CA, USA). All chemicals were from Sigma-Aldrich (St.
Louis, MO, USA) except where indicated.
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Crude culture supernatants representing specific BoNT/B
strains were produced by incubating subcultures of each
strain for 5 days at 30–35 °C. After centrifugation, super-
natants were removed and filtered through 0.22-μm filters.
The filtered supernatants were tested for upper limits of
toxicity using the mouse bioassay, which indicated that the
toxins were all present at concentrations of ≤10 μg/mL.
Information on the strains used in these studies is listed in
Table 1.
Neurotoxin extraction and digestion
Monoclonal antibodies 1B18 and B12.1 [22] which bind the
heavy chain of the toxin obtained from the laboratory of Dr.
James Marks at the University of California, San Francisco,
were immobilized and crosslinked to the Dynabeads® Pro-
tein G using 30 μg of antibody diluted into 500 μL of PBS
for every 100 μL of Dynabeads® Protein G. Cross-linked
IgG-coated Dynabeads® were stored in PBS-Tween buffer
(PBS with 0.05% Tween® 20) at 4 °C for up to 2 days. For
the BoNT extraction assay, an aliquot of 20 μL of antibody-
coated beads was mixed for 1 h with a solution of 200 μLo f
each culture supernatant and 300 μL of PBS with 0.01%
Tween (PBST) buffer. After mixing for 1 h with constant
agitation at room temperature, the beads were washed twice
in 1 mL each of PBST and once in 100 μL of water. The
beads were reconstituted in 15 μL of 50-mM ammonium
bicarbonate, pH07 . 5( t r y p t i cb u f f e r )a n d2μLo fs t o c k
trypsin, and digested for 5 min at 52 °C
23. Following diges-
tion, the supernatant was then removed from the beads and
1 μL of 10% TFA was added to the supernatant. A second,
independent digestion (5 min at 52 °C) was performed by
reconstitution of the beads in 15 μL of tryptic buffer and
addition of 1 μL of chymotrypsin diluted to 0.2 mg/mL in
the tryptic buffer. After digestion, each supernatant was then
removed from the beads and 1 μL of 10% TFA was added.
Each digested sample was analyzed separately.
Mass spectrometric analysis of BoNT
After digestion, 5 μL of the sample was injected onto a
Waters NanoAcquity C18 5 μmU P L Ct r a pc o l u m n
(180 μm ID and 2 cm long) and separated on a Waters
NanoAcquity C18 1.7 μm UPLC column, 100 μm ID, and
10 cm long (Waters, Milford, MA, USA). After a trap-
loading flow rate of 5 μL/min for 5 min, the peptides were
eluted from the column at a flow rate of 500 nL/min using
the following gradient conditions, where A is water with
0.1% formic acid and B is 100% acetonitrile with 0.1%
formic acid: A095% and B05% at 0 min; A085% and
B015% at 10 min; A065% and B035% at 60 min; A0
30% and B070% at 62 min; hold for 5 min, A095% and
B05% at 70 min; hold for 10 min.
Peptides eluting from the column were introduced into a
7-Tesla linear trap (LTQ)-FT-ICR instrument (Thermo Elec-
tron, San Jose, CA) using an Advion TriVersa NanoMate
nanoelectrospray ion source interface equipped with an LC
coupler (Advion, Ithaca, NY, USA). The instrument was
operated in data-dependent acquisition mode to automati-
cally switch between MS and MS/MS analysis. The FT-
ICR-MS was used for MS acquisition with a resolution of
25,000 from 400 to 1,600 m/z. Simultaneously, the linear
ion trap was used for MS/MS analysis of the five most
abundant ions in each MS scan. Automatic gain control
was used to accumulate ions for FT-ICR-MS analysis with
a target value of 1,000,000 and 200,000 for MS and MS/MS
analysis, respectively. Collision energy of 35% was utilized
in the linear ion trap to fragment the tryptic digest fragments.
Construction of an amino acid substitution database
FASTA databases were generated using the proteolytic
cleavage products of the sequence of BoNT/B1 as database
entries, and single substitutions in every proteolytic cleav-
age product were included as an entry in the FASTA data-
base (19 other possible amino acids per site). First, in silico
digestions of BoNT/B1 based upon the known cleavage
rules of trypsin and chymotrypsin, respectively, were com-
pleted and collated into cleavage product lists. Subsequently,
each peptide was looped through one amino acid at a time,
with each particular amino acid changed one at a time to one
ofthe19otheraminoacids,witheachchangedpeptidewritten
to file as an entry in the NCBI FASTA format. Thus, using
trypsin as the enzyme, the BoNT/B1 sequence generated 157
possible cleaved peptides, and with the change of one amino
acid at a time, the trypsin FASTA database contained 23,899
theoretical sequences. Using chymotrypsin as the proteolytic
Table 1 Strain information on culture supernatants used for this study
Sample Strain NCBI accession no.
B1 Okra AB232927
B1 CDC 1656 EF028396
B1 CDC 1758 EF033127
B2 CDC 1828 EF051571
B2 Prevot 59 EF033128
B2 Prevot 25 EF033129
B3 CDC 795 EF028400
B4 (nonproteolytic) Eklund 17B EF051570
B5 (bivalent) An436 EF028397
B7 Bac-04-07755 JQ354985
B7 NCTC3807 JN120760
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with 24,033 theoretical sequences. All machine code to gen-
erate the two FASTA databases was written in-house using
Microsoft Visual C# 2008.
Searching of data against databases
Peak lists for all MS/MS spectra were extracted using Mascot
Distiller (Matrix Science Inc., Boston, MA, USA, version
2.2.0) and merged together using Mascot Daemon (Matrix
Science Inc, Boston, MA, USA, version 2.2.2). Database
searches were conducted using Mascot (Matrix Science Inc,
Boston, MA, USA, version 2.2.0) against a database generat-
ed by extracting entries from the NCBI non-redundant data-
base using “Clostridia” as the extraction parameter. Mascot
parameters were applied as follows for standard protein data-
base searching: nine maximum missed cleavages, non-
specific enzyme, peptides with up to +4 charge, MS1 toler-
ance of 20 ppm and MS/MS tolerance of 0.8 Da, and carba-
midomethyl, deamidation, and oxidation modifications
allowed. Mascot parameters were applied as follows for ami-
no acid substitution database searching: nine maximum
missed cleavages, semi-tryptic (K and R) and semi-
chymotryptic enzyme selectivity, peptides with up to +4
charge, MS1 tolerance of 20 ppm and MS/MS tolerance of
0.5 Da, semi-specific searches included one non-specific
cleavage site located on either the N or C terminus of the
peptide. MS/MS-based peptide and protein identifications
were validated using Scaffold (version Scaffold_2_00_06,
Proteome Software Inc., Portland, OR, USA). Peptide identi-
fications were accepted if they could be established at greater
than 95.0% probability as specified by the Peptide Prophet
algorithm. Protein identifications were accepted if they could
be established at greater than 99.0% probability as specified
bytheProteinProphetalgorithm,andiftheycontained atleast
three peptides with unique amino acid sequences.
DNA sequencing and phylogenetic analysis
Strains were grown anaerobically in tryptone–peptone–glu-
cose–yeast broth and DNAwas isolated as reported [23]. The
bont/b gene was amplified and subjected to Sanger sequenc-
ing. DNA alignment of the obtained full-length sequences of
the bont/b genes with already published sequences followed
by phylogenetic analysis and construction of the dendrogram
was carried out as described previously [10].
Results
Peptides derived from the tryptic and chymotryptic diges-
tion of BoNT/B1 Okra, B2 Prevot 25, BoNT/B3 CDC 795,
BoNT/B4 Eklund 17B, and BoNT/B5 An436 were analyzed
by MS/MS with an LTQ-FT-ICR mass spectrometer and the
data were compared against a standard protein database. All
five BoNT proteins were correctly identified as BoNT/B1,
B2, B3, B4, or B5 despite the high level of sequence
similarity (as high as 98.4%). Table 2 is a list of peptides
from the digests of these neurotoxins which were identified
by MS/MS and are unique for each subtype. The overall
percent coverage for each of the proteins was 76%, 76%,
66%, 75%, and 74%, respectively. Because these listed
peptides are unique for each of the subtypes, they serve as
biomarkers that identify each of the different BoNT/B
subtypes.
Although these five BoNT proteins show as much as
98.4% identity, there are still many differences in the amino
acid sequence among these toxins, and these differences can
be exploited to distinguish toxins from each other by mass
spectrometry. For example, there are 56 amino acids that
differ between BoNT/B1 Okra and B2 Prevot 25. Upon MS
examination of BoNT/B1 Okra and B2 Prevot 25, we
obtained evidence for 34 of these amino acids or approxi-
mately 60% of the differing amino acid residues.
The 34 amino acid differences were identified by query-
ing the MS/MS data against a protein database that included
a protein sequence (BoNT/B2 Prevot 25) containing all 56
differing amino acids. However, protein sequences of any
novel BoNT/B subtypes would not be present in the protein
database and therefore, a unique new subtype of BoNT/B
would simply be identified as the closest match that exists
within the database. To optimize identification of novel
subtypes, we developed an amino acid substitution database
in which every amino acid within the BoNT/B1 Okra se-
quence was mutated in silico to 19 other possibilities. It is
important to note that this amino acid substitution database
was not intended to include all amino acid differences, as it
does not account for more than one mutation within a tryptic
or chymotryptic fragment, but rather suggests the presence
of a new subtype or variant, and assists in the differentiation
of toxins from botulism outbreaks. Although the database
would certainly be more inclusive through the inclusion or
more than one mutation within a tryptic or chymotryptic
fragment, it would also require substantially more time to
search against, thus lengthening the time frame for
identification.
We first tested the use of the amino acid substitution
database by digesting the BoNT/B2 Prevot 25 and treating
it as an unknown while searching the data in the /B1 Okra
amino acid substitution database. BoNT/B1 Okra and
BoNT/B2 Prevot 25 are fairly similar (95.6%) with 56
amino acids that differ. Upon querying the data from the
digests of BoNT/B2 Prevot 25 against the /B1 Okra amino
acid substitution database, MS/MS data were found to sup-
port the identity of ten amino acid differences; the MS/MS
spectra which demonstrate the presence of some of those
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sent 18% (10 of 56) of the total known differences
Table 3 lists the peptides with amino acid differences that
were discovered through the use of the amino acid substi-
tution database. Figure 1a is the MS/MS of the sequence
970IIWTLTDINGK
980 which includes the difference from I
to T in position 975. In addition to the altered intact peptide
ion at m/z 637.36, the mass difference between y5 at m/z
546.2 and y6 at m/z 647.3 is 101 Da, which corresponds to a
threonine rather than an isoleucine. Additionally, the mass
difference between b5 at m/z 627.3 and b6 at m/z 728.2 is
101 Da, which corresponds to a threonine rather than an
isoleucine. This MS/MS spectrum indicates the existence of
the amino acid substitution from I to T in position 975.
Figure 1b is the MS/MS of the sequence
599DFVIEANKSSTM
610 with the mutation from N to S in
position 608. The altered intact peptide doubly charged ion
at m/z 671.32, and the mass difference of 87 Da between b9
at m/z 1,004.4 and b10 at m/z 1,091.3, demonstrate the
existence of a serine rather than an asparagine. Figure 1c
is the MS/MS of the sequence
1114DSSVGEILTR
1123 which
includes the mutation from P to S in position 1116. In
addition to the altered intact peptide ion at m/z 538.79, the
mass difference between y7 at m/z 787.3 and y8 at m/z 874.5
is 87 Da, which corresponds to a serine rather than a proline;
this confirms that this peptide has an amino acid substitution
in position 1116. The discovery of these ten amino acids
indicates that the amino acid substitution database can be
used for de novo discovery of many of the differences
present in the B2 Prevot 25 sequence. It also demonstrates
that a previously unknown subtype of BoNT/B could be
identified as “novel” through the use of the amino acid
substitution database.
We then used this approach to distinguish BoNT/B1
toxin variants, whose amino acid sequences are more similar
to BoNT/B1 Okra than that of a different BoNT/B subtype,
like BoNT/B2 Prevot 25. Two strains identified as produc-
ing BoNT/B1, but whose protein sequences were not
Table 2 Peptides from the digests of BoNT/B1–/B5 which are unique
for each subtype and were identified by MS/MS
Subtype Peptide sequence
BoNT/B1
(Okra)
384NLLDNEIYTIEEGFNISDKDMEK
406
595QIVNDFVIEANK
606
692WSDMYGLIVAQWLSTVNTQFYTIK
715
721ALNYQAQALEEIIKYR
736
759LNEGINQAIDNINNFINGCSVSYLMK
784
833TIMPFDLSIY
842
843TNDTILIEMFNK
854
869YKDNNLIDLSGY
880
1003FVTITNNLNNAK
1014
1021LESNTDIKDIR
1031
1057YFSIFNTELSQSNIEER
1073
1242FYESGIVFEEYK
1253
BoNT/B2
(Prevot 25)
1029NIGEVIANGEIIFK
1042
1162KEDYIYLDFFNSNR
1175
1179VYAYKDFKEEEK
1190
1242FYESGIVLKDYKNYF
1256
BoNT/B3
(CDC 795)
255FFMQSTADIQAEELYTFGGQDPR
277
884VEVYNGVELNDKNQFK
899
910VTQNQDIIF
918
BoNT/B4
(Eklund
17B)
254KFFMQSTDTIQAEELYTFGGQDPSIISPSTDK
285
329FVEDSEGKYSIDVESFNK
346
350SLMFGFTEINIAENYK
365
384NLLDNEIYTIEEGFNISDKNMGK
406
441VPGICIDVDNENLFFIADK
459
472VEYNTQNNYIGNDFPINELILDTDLISK
499
529VFTDENTIFQYLY
541
542SQTFPLNIR
550
623IGLALNVGDETAK
635
737YNIYSEEEKSNININFNDINSK
758
759LNDGINQAMDNINDFINECSVSYLMK
784
814LYLIGSVEDEK
824
833TIIPFDLSTYTNNEILIK
850
936YRNDDIQNYIHNEYTIINCMK
956
1015IYINGTLESNMDIK
1028
1029DIGEVIVNGEITFK
1042
1042KLDGDVDRTQF
1052
1057YFSIFNTQLNQSNIK
1071
1111LVKDSSVGEILIR
1123
1163EDYIHLDFVNSNEEWR
1178
1184NFKEQEQK
1191
1192LFLSIIYDSNEFYK
1205
1226KDEESTDDIGLIGIHR
1241
1242FYESGVLR
1249
1272KSNLGCNWQFIPKDEGWTE
1290
BoNT/B5
(An436)
472IAYNTQNNYIDNDFSINELILDTDLISK
499
500IELPSENTESLTDFNVYVPEYK
521
677IIETINSALTK
687
746SNINIDFNDVNSK
758
Table 2 (continued)
Subtype Peptide sequence
794LLDFDNTLR
802
833TSIPFDLSTY
842
855YNSDILNNIILNLR
868
983SVFFEYSIK
991
1032EVIANDEIIFK
1042
1043LDGNIDRTQFIWMK
1056
Residues which make each peptide unique for the given subtype are
bolded
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strain CDC 1656 has nine amino acid differences compared
to BoNT/B1 strain Okra, and two of the nine differences
were discovered through the use of the amino acid substi-
tution database, as seen in Table 4. Strain CDC 1758 has
only three amino acid differences for a variation of less than
0.3%, and one of those differences was discovered through
the use of the amino acid substitution database as seen in
Table 4.
Two additional strains expressing BoNT/B2, with the
sequence of their bont genes confirmed by full-length se-
quencing, but whose protein sequences were not entered
into the protein database, were also analyzed using this
approach. BoNT/B2 strain CDC 1828 has 58 amino acid
differences compared to BoNT/B1 strain Okra, and, as
indicated in Table 5, seven of those differences were dis-
covered through the use of the amino acid substitution
database. This corresponds to 23% of the total number of
peptides which have a single amino acid difference. BoNT/
B2 strain Prevot 59 has 56 amino acid differences, and as
indicated in Table 5, seven of those differences were dis-
covered by querying the amino acid substitution database,
corresponding to 26% of the total number of peptides which
have a single difference.
As a final demonstration of our ability to identify a
BoNT/B sample as “novel”, we analyzed several samples
which were determined to contain BoNT/B after testing by
mouse bioassay and Endopep-MS [22]. However, these
samples had not yet been subjected to DNA analysis, so
there was no subtype or strain identification on the samples.
After digestion, MS/MS analysis, and searching of the stan-
dard protein database, one of the samples was tentatively
identified as BoNT/B2 L-590 with 48% sequence coverage,
with the chromatogram shown in Fig. 2. After searching the
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Fig. 1 MS/MS spectra of the
precursor ions at m/z 637.36
(1A), 671.32 (1B), and 538.79
(1C) corresponding to
doubly-charged peptides
IIWTLTDINGK (1A),
DFVIEANKSSTM (1B), and
DSSVGEILTR (1C) from the
digests of BoNT/B2. The spec-
tra were obtained by LC-MS/
MS on an FT-ICR mass spec-
trometer, with MS analysis in
the FT-ICR cell and MS/MS
analyses within the LTQ por-
tion. Residues which are set in
bold indicate amino acid
substitutions
Table 3 Peptides from the di-
gest of both BoNT/B1 and /B2
with amino acid differences that
were discovered through the use
of the amino acid substitution
database
Amino acid position Difference (B2 Prevot 25) Normal (B1 Okra)
472-484 IEYNTQSNYIENR IEYNTQSNYIEND
599-610 DFVIEANKSSTM DFVIEANKSNTM
850-868 EIFNKYNSEILNNIILNLR EMFNKYNSEILNNIILNLR
876-887 DLSGYGANVEVY DLSGYGAKVEVY
910-923 VTQNQNIIFNSMFL VTQNQNIIFNSVFL
970-980 IIWTLTDINGK IIWTLIDINGK
976-992 DINGKTKSVFFEYSIRE DINGKTKSVFFEYNIRE
1057-1071 YFSIFNTELSQSNIK YFSIFNTELSQSNIE
1072-1084 EIYKIQSYSEYLK ERYKIQSYSEYLK
1114-1123 DSSVGEILTR DSPVGEILTR
220 S.R. Kalb et al.MS/MS data from this sample against the amino acid sub-
stitution database, five differences compared to BoNT/B2
L-590 were found, indicating that this protein is not BoNT/
B2 L-590. Specifically, these five differences were found to
be V597I/L, S746I/L, L877S, S1010I/L, and A1035V, and
MS/MS evidence for some of these differences are shown in
Fig. 3. Before this work, amino acid positions 597, 746, and
877 were not known to have differences in any strain or
subtype of BoNT/B, so these differences are completely
new for BoNT/B.
Figure 3a is the MS/MS of the sequence
595QIIDDF-
VIEANK
606 which includes the mutation from V to I in
position 597. In addition to the altered intact peptide ion at
m/z 702.9, the mass difference between y9 at m/z 1,050.6
and y10 at m/z 1,163.6 is 113 Da, which corresponds to a
leucine or isoleucine rather than a valine. Residue 1010, an I
or L in this sample, is an L in some BoNT/B1 and B4, but
this difference is new for any BoNT/B2 where this residue is
typically a serine. Figure 3b is the MS/MS of the sequence
1001WFFVTITNNLDNAK
1014 which includes the mutation
from S to L in position 1010. The intact peptide ion at m/z
841.93 is different from m/z 828.90, which appears in all
other BoNT/B2. The mass difference between y4 at m/z
447.4 and y5 at m/z 560.4 is 113 Da, which corresponds to
a leucine or isoleucine. Furthermore, the mass difference
between b9 at m/z 1,123.6 and b10 at m/z 1,236.5 is 113 Da,
which corresponds to a leucine or isoleucine. Residue 746 is
an S in all other BoNT subtypes and was not known until
now to be mutated. Similarly, residue 877 is an L in all other
BoNT/B subtypes. Residue 1035 is a V only in BoNT/B4
subtypes, and this difference is new for any BoNT/B2.
After discovering these novel point mutations in the
BoNT/B sample, the bont/b gene was sequenced confirming
the above point mutations as well as 45 other amino acid
differences, defining this sample as a new subtype of BoNT/
B, BoNT/B7. After adding this new BoNT/B sequence to
our standard database and searching the MS/MS data
against the updated database, the top hit was the new
BoNT/B7 Bac-04-07755 strain. The percent coverage in-
creased from 48% coverage with BoNT/B2 L-590 to 68%
coverage with BoNT/B7 Bac-04-07755 as seen in Fig. 4,
further verifying that this is a more accurate identification of
the BoNT/B in this sample.
Discussion
Our experiments demonstrate the ability to identify the
subtype (B1-B5, B7) of a BoNT/B using both the MS/MS
with a standard protein database or with our amino acid
substitution database. The combination of the two methods
also can identify the subtype, a toxin variant within a sub-
type, or identify a unique subtype, not previously discov-
ered. In previous work, we demonstrated that BoNT
subtypes could be distinguished from each other by MS
[12,13]. While Kull et al. used MALDI-TOF MS to differ-
entiate between BoNT/B1 and B4, we previously analyzed
the tryptic peptides of BoNT/A1 and A2 by LC-MS/MS.
Table 4 Locations and type of mass-spectrometric identified amino acid differences in two additional strains of BoNT/B2 as compared to BoNT/
B1 Okra
B1 Okra
residue
B1 CDC
1656 residue
B1 CDC
1758 residue
B1 Okra peptide
identified by MS/MS
B1 CDC 1656 peptide
identified by MS/MS
B1 CDC 1758 peptide
identified by MS/MS
70C 70W 70C DVCEYYDPDYLNTNDKK DVWEYYDPDYLNTNDK DVCEYYDPDYLNTNDK
1250E 1250K 1250K FYESGIVFEEYK FYESGIVFKEYK FYESGIVFK
Table 5 Locations and type of
mass spectrometric identified
amino acid differences in two
additional strains of BoNT/B2 as
compared to BoNT/B1 Okra
B1 Okra
residue
B2 CDC 1828
residue
B2 Prevot 59
residue
B2 CDC 1828 peptide
identified by MS/MS
B2 Prevot 59 peptide
identified by MS/MS
608N 608S 608S DFVIEANKSSTM DFVIEANKSSTM
851M 851I 851I EIFNKYNSEILNNIILNLR
870K 870R 870R YNSEILNNIILNLRYR
883K 883N 883N DLSGYGANVEVY
921V 921M 921M VTQNQNIIFNSMFL VTQNQNIIFNSMFL
975I 975T 975T IIWTLTDINGK
1031R 1031G 1031G DIGEVIANGEIIFK
1071E 1071K 1071K SIFNTELSQSNIK YFSIFNTELSQSNIK
1073R 1073I 1073I EIYKIQSYSEYLK
1116P 1116S 1116S DSSVGEILTR DSSVGEILTR
De novo subtype and strain identification of botulinum neurotoxin 221Although these two A subtypes are approximately 90%
homologous, we demonstrated that we could exploit the
10% of the protein that was unique, to identify the toxin as
BoNT/A1 or /A2. The amino acid sequences of BoNT/B1–
B5 are more conserved than A1 and A2. They differ by as
little as 1.6% (in the case of BoNT/B2 and /B3), while the
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222 S.R. Kalb et al.difference between /A1 and /A2 is 10.1%. Although these
five BoNT/B subtypes are very similar, they still differ by as
few as 21 amino acids, which was sufficient for subtype
identification through enzymatic digestion and subsequent
mass spectrometric analysis.
The use of two different enzymes (trypsin and chymo-
trypsin) to digest the samples contributes to the high percent
coverage of these proteins with a mass above 150 kDa. A
high percentage of coverage is critical for novel BoNT
subtype and toxin variant identification as with increasing
coverage (amino acid sequence for which there is mass
spectrometric evidence), there is a higher likelihood of
identifying more amino acid differences. Through the use
of the combined enzymatic digestions and LC-MS/MS anal-
ysis of the resultant peptides, we were able to obtain 77%,
76%, 66%, 75%, and 74% amino acid coverage of BoNT/
B1, /B2, /B3, /B4, and /B5, respectively. This high sequence
coverage allowed us to use mass spectrometry to distinguish
each of these highly similar proteins from each other, and in
the case of /B1 and /B2, to identify 34 of the 56 amino acids
which differed between these two proteins. Although less
than 40% of the differing residues could not be detected by
mass spectrometry; nonetheless, the identification of 34
amino acid differences provides an effective method allow-
ing for a definitive identification of BoNT/B as either the
/B1 or /B2 subtype. Furthermore, these studies represent the
first protein sequencing method applied to BoNT/B2, B3,
B4, and /B5.
BoNT/B5 is a bivalent toxin producer, producing both
BoNT/B5 and a lesser amount of BoNT/F or A. Due to the
specificity of the capture antibodies, we can examine biva-
lent toxin strains without interference from the second toxin.
The detection of two toxins in a preparation can be difficult
for some other identification methods. Identification of the
toxin as a /B5 through proteomic analysis might indicate
that there is a second toxin present which could have an
effect on botulism treatment. Additionally, the /B4 subtype
is associated with nonproteolytic BoNT/B strains. These
strains are not always reliably detected using other methods,
but the proteomic technique discussed here can easily iden-
tify BoNT/B4.
If the amino acid sequence of BoNT/B2 Prevot 25 had
not been in the protein database, as would be expected for an
unknown subtype or toxin variant of BoNT/B, we still
would have identified the protein as discrete from that of
BoNT/B1 Okra through the use of the amino acid substitu-
tion database. The creation of the database allowed the “de
novo” identification of ten amino acid differences. Although
not all of the theoretical differences were discovered using
this method, there were enough differences to assign the
identity of BoNT/B2 as similar to BoNT/B1, but not as
BoNT/B1—a more precise identification than the de facto
assignment of BoNT/B1. Since our goal is not to identify all
possible amino acid differences, but identify a BoNT protein
as an existing subtype or a novel toxin variant and to
identify differences in toxins from ongoing botulism out-
breaks; these results demonstrate that this goal can be
achieved through the use of this technique.
Totestthe abilityofthe methodtodetectdifferenceswithin
subtypes (<1.4% amino acid variation which is ~21 amino
acids), we obtained two BoNT/B1 samples whose amino acid
sequences were not in the protein database, digested those
proteins,andanalyzedtheresultantfragmentsbyLC-MS/MS.
Searchingthe dataagainst anaminoacidsubstitutiondatabase
of BoNT/B1 Okra allowed for identification of two of nine
possible differences in one strain and one of three possible
differences in another strain which is sufficient to indicate
differences in outbreak samples.
The identities of residues 70 and 1250 are critical for
identification of these strains as three separate proteins.
According to data listed in Table 4, BoNT/B1 Okra contains
70C and 1250E, BoNT/B1 CDC1656 contains 70W and
1250K, and BoNT/B1 CDC 1758 contains 70C and
1250K. Because each of these samples has a unique com-
bination of identities of residues 70 and 1250, these three
proteins can be identified as three separate protein identities.
Again, although not all differences were discovered through
this technique, the goal of strain differentiation of BoNT/B1
by mass spectrometry was achieved, as these three samples
were identified as having very similar yet distinctly unique
protein sequences. Additionally, this work reports the first
protein comparison of multiple strains of the same BoNT
subtype by MS techniques.
PVTINNFNYN DPIDNNNIIM MEPPFARGTG RYYKAFKITD RIWIIPERYT
FGYKPEDFNK SSGIFNRDVC EYYDPDYLNT NDKKNIFLQT MIKLFNRIKS
KPLGEKLLEM IINGIPYLGD RRVPLEEFNT NIASVTVNKL ISNPGEVERK 
KGIFANLIIF GPGPVLNENE TIDIGIQNHF ASREGFGGIM QMKFCPEYVS 
VFNNVQENKG ASIFNRRGYF SDPALILMHE LIHVLHGLYG IKVDDLPIVP 
NEKKFFMQST DAIQAEELYT FGGQDPSIIT PSTDKSIYDK VLQNFRGIVD 
RLNKVLVCIS DPNININIYK NKFKDKYKFV EDSEGKYSID VESFDKLYKS 
LMFGFTETNI AENYKIKTRA SYFSDSLPPV KIKNLLDNEI YTIEEGFNIS 
DKDMEKEYRG QNKAINKQAY EEISKEHLAV YKIQMCKSVK APGICIDVDN
EDLFFIADKN SFSDDLSKNE RIEYNTKNIY IENYFSINEL ILDTDLISGI 
ELPSENTESL TDFNVDVPVY EKQPAIKKIF TDENTIFQYL YSQTFPLDIR 
DISLTSSFDD ALLFSNKVYS FFSMDYIKTA NKVVEAGLFA GWVKQIIDDF 
VIEANKSSTM DKIADISLIV PYIGLALNVG NETAKGNFEN AFEIAGASIL 
LEFIPELLIP VVGAFLLESY IDNKNKIIKT IDNALTKRVE KWIDMYGLIV 
AQWLSTVNTQ FYTIKEGMYK ALNYQAQALE EIIKYKYNIY SEKEKLNINI 
DFNDINSKLN EGINQAIDNI NNFINECSVS YLMKKMIPLA IEKLLDFDNA 
LKKNLLNYID ENKLYLIGSV EEEKSKVDKF FKTIIPFDLS MYTNNTILIE 
MVNKYNSEIL NNIILNLRYR DNNLIDSSGY GAKVEVYNGV ELNDKNQFKL
TSSANSKIKV TQNQNITFNS MFLDFSVSFW IRIPKYKNDG IQNYIHNEYT 
IINCMKNNSG WKISIRGNRI IWTLTDINGK TKSVFFEYSI REDISDYINR 
WFFVTITNNL DNAKIYINGK LESNIDIRDI REVIVNGEII FKLDGEIDRT 
QFIWMKYFSI FNTELSQSNV KEIYKIQSYS KYLKDFWGNP LMYNKEYYMF 
NAGNKNSYIK LVKDSSVGEI LTRSKYNQNS NYINYRNLYI GEKFIIRRKS
SSQSISDDIV RKEDYIYLDF FNSNREWRVY AYKNFKGQEE KLFLANIYDS 
NEFYKTIQIK EYDEQPTYSC QLLFKKDEES TDEIGLIGIH NFYESGILFK 
DYKDYFCISK WYLKEVKKKP YSSNLGCNWQ FIPKDEGWTE 
Fig. 4 Amino acid sequence of BoNT/B7 Bac-04-07755. Residues in
red comprise the 68% sequence coverage for which MS/MS evidence
was obtained
De novo subtype and strain identification of botulinum neurotoxin 223Strain variance exists in most of the BoNT subtypes, and
BoNT/B2 is not an exception. We obtained two BoNT/B2
samples whose sequences were not in the protein database,
digested those samples, and the resultant peptides were
analyzed by LC-MS/MS. The data were then queried against
the amino acid substitution database generated from the
BoNT/B1 Okra sequence. Seven to ten of the possible 56–
58 amino acid differences were discovered using this tech-
nique. Note that searching the data through the amino acid
substitution database yielded one to two amino acid differ-
ences for toxin variants (BoNT/B1) and seven to ten amino
acid differences for subtype (BoNT/B2) differences. There-
fore, this technique could allow for a tentative identification
of a novel protein or a new BoNT/B subtype or toxin
variant, depending on the number of amino acid differences
discovered through this technique.
In fact, the number of amino acid differences was critical
toward our tentative identification of the BoNT/B7 sample
as a new subtype rather than a new BoNT/B2 strain/toxin
variant, as this sample contained five novel amino acid
differences, or greater than the number of one to two that
we saw for strain differentiation. BoNT/B7 strain Bac-04-
07755 originates from a recent infant botulism case in New
York. Interestingly, the identical novel subtype BoNT/B7
was independently discovered by BGD and co-workers by
“classical” DNA sequencing of strain NCTC 3807 (National
Collection of Type Cultures, UK). Strain NCTC 3807 was
originally isolated in 1921 from soil from the Blue Ridge
Mountains of Virginia and later deposited into the NCTC
strain collection [24], meaning that this “old” strain is still
circulating within the USA. Noteworthy, this new subtype
BoNT/B7 has been reported to differ from other BoNT/B
molecules, as the toxin was not recognized by a mAb in a
specific ELISA [5], again justifying that this toxin should be
named a novel BoNT/B subtype.
Indeed, DNA sequencing and subsequent phylogenetic
analysis [10] showed that strains Bac-04-07755 and NCTC
3807 form a separate cluster, here designated as BoNT/B7,
adjacent to the BoNT/B4 cluster as seen in the dendrogram
in Fig. 5.
Although the dendrogram shows that its closest relative is
BoNT/B4, searching the MS/MS data of BoNT/B7 against
the known protein database yielded BoNT/B2 as the most
closely related protein. This is simply because unlike DNA
sequencing, the mass spectrometer did not identify 100% of
the protein and as a result could not be used solely to
determine evolutionary relatedness. The portion of the pro-
tein identified by mass spectrometry was most similar to
BoNT/B2. This is not problematic as the goal of this work is
not to identify the closest neighbor of the toxin, but rather to
identify the toxin as a new subtype or toxin variant.
Because our technique identified single-point mutations
within a peptide, conservative data interpretation is a key
component of correct identification. Mass spectrometry data
do not always provide evidence for every amino acid within
a peptide, so a mass spectrum could be misinterpreted and
provide misleading results. Specifically, it is not enough for
the intact peptide mass and the fragmentation pattern to
match a new peptide; it is critical that product ions be
obtained to prove the identity of the single mutated residue.
As an example, it was initially suspected that the identity of
a peptide at m/z 888.94 was the doubly charged peptide
YFSIFNTELSQSVIE, with a single amino acid substitution
from the sequence of YFSIFNTELSQSNIE. Product ions
from y4 to y11 appeared to confirm this finding. However,
with the absence of the y2 and y3 or b12 and b13 ions, this
finding was not confirmed. After PCR sequencing, this
peptide was found to have the identity of YFSIFN-
TELSQNVK, or two differences within the peptide. This
peptide also produced an m/z of 888.94 and the same y4 to
y11 product ions as produced with the peptide sequence
YFSIFNTELSQSVIE. Because our amino acid substitution
database only supplied single-point mutations within a pep-
tide, the correct possibility was not considered, and a less
conservative data analysis would have produced a mislead-
ing result.
By examining the tryptic and chymotryptic digests of
BoNT/B by mass spectrometry, a toxin can be first identi-
fied as BoNT/B and then further identified as subtype /B1,
/B2, /B3, /B4, or /B5 similar to previous experiments which
identified BoNT/A as A1 or A2 [12]. Additionally, we have
demonstrated that novel BoNT/B subtypes or toxin variants
could be reported using the point mutation search approach,
rather than incorrectly identified as the most similar protein
match in the database of known protein sequences. Al-
though the use of an amino acid substitution database does
B5.258 Bf An436 
B1.155 okra 
B1.165 CDC 1758 
B1.163 CDC 1656 
B7.131 Bac-04-07755 
B7 NCTC 3807 (RKI) 
B4.257 Eklund 17B 
B3.506 CDC 795 
B2.164 CDC 1828 
B2.306 Prevot 25 NCASE 
B2.305 Prevot 59  6 amino acid differences
Fig. 5 Dendrogram of proteins
used in this study. Because the
horizontal line represents the
distance for six amino acids, the
closer the subtypes in distance
the fewer differences in amino
acid between them
224 S.R. Kalb et al.not identify all of the amino acid differences present in a
novel toxin variant or subtype of BoNT/B, it identifies
enough of the amino acid differences to enable classification
of a toxin as a new BoNT/B subtype or even a new toxin
variant. Such information is especially important for foren-
sics and epidemiological purposes in order to identify the
possible source of an outbreak or the spread of BoNT-
producing Clostridium species.
Because this information can be obtained without DNA, it
is possible to identify BoNT/B to or below the subtype level
using protein-based analysis. This technique is, to our knowl-
edge, the only protein-based technique for BoNT subtyping
and toxin variant identification, providing a relatively rapid
and accurate protein subtyping tool for analysis of botulism
samples. Additionally, such information can be obtained in a
fewdaysratherthanafewweeks,makingitavaluabletoolfor
epidemiologists who are tracking botulism outbreaks on a
real-time basis. Currently, the amino acid substitution data-
base is searched manually, and one future goal is to automate
this process. We are optimistic that automation of data search-
ing would allow for novel BoNT subtype and toxin variant
identification within 1 day as sample preparation and data
acquisition occurs in only a few hours.
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